pharma · Geographic Atrophy · Geographic Atrophy Secondary to Age-related Macular Degeneration · APLS
Genzyme Europe
Apellis Europe B.V.
Genzyme Europe trial registry — 27 ClinicalTrials.gov studies with program phase, status, and indication context.
Gooimeer 10, Naarden, None 1411 DD, NL, WALTHAM, MA HQ
1981 Founded
273 Employees
Public company Type
APLS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Gooimeer 10, Naarden, None 1411 DD, NL, WALTHAM, MA
- Founded
- 1981
- Employees
- 273
- Programs
- 20
- Drugs
- 5
- Patents
- 24
Genzyme Europe clinical trials
Registry index of 27 ClinicalTrials.gov studies linked to Genzyme Europe programs — each row shows trial ID, program name, phase, status, and indication.
Genzyme Europe trial registry — 27 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Genzyme Europe.
-
Virtual Reality (VR) Contrast Function Test — Unknown
Clinical update -
Pegcetacoplan — Phase 2
Clinical update -
PEGCETACOPLAN (APL-2) — Phase 3
Clinical update -
APL-3007, pegcetacoplan (APL-2) — Phase 2
Clinical update -
APL-2, Pegcetacoplan — Phase 3
Clinical update -
APL-9 — Phase 2
Clinical update -
APL-2 — Phase 3
Clinical update -
Pegcetacoplan — Phase 3
Clinical update
Trial registry
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ - NCT07215390CT.gov ↗
APL-3007, pegcetacoplan (APL-2)
Geographic Atrophy Secondary to Age-related Macular Degeneration